A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen.
A retrospective and prospective data collection study on 27 consecutive subjects with adenocarcinoma who were treated using the MyVaccx system by Dr. Gary Onik. Retrospective data were collected on the treatment with the immunotherapy system and prospective data will be collected as they are prospectively monitored through their normal standard of care for their original cancer.
Checked against the public recordLast updated Jul 22, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Gary Onik MD
- Interventions being studied
- Drug: Immunotherapeutic Agents; Device: Ablation
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Treatment with the MyVaccx System * Greater than 18 years of age * Signature of the informed consent Exclusion Criteria: * 2 subjects treated with the MyVaccx System with known visceral disease
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- The Center for High Risk and Recurrent Prostate CancerFort Lauderdale, Florida
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 22, 2020. Always confirm current availability with the study team.